share_log

Third Largest Player In Baby Formula Jumps In To Ease Shortage In US

Third Largest Player In Baby Formula Jumps In To Ease Shortage In US

嬰兒配方奶粉第三大廠商加入緩解美國奶粉短缺
Benzinga Real-time News ·  2022/05/18 16:03
  • Europe's Nestlé SA (OTC:NSRGF) is ramping up hypoallergenic (HA) baby formula production to alleviate the shortage in U.S. supermarkets.
  • In a statement sent to Fortune, Nestlé said it "significantly increased" Gerber Good Start Extensive HA production from the Netherlands and Alfamino from Switzerland, both used to treat babies that respond allergically to sugars like lactose.
  • Nestlé declined to be more specific on the size of increased shipments.
  • A recall by Abbott Laboratories (NYSE:ABT), persistent supply-chain issues, and a highly concentrated market combined to form what one consumer goods expert calls a "perfect storm."
  • Related: US Lawmakers Reveal FDA Emergency Funds Bill To Tackle Baby Formula Shortage: Reuters.
  • The most recent statistics suggest Abbott had a 43% market share, while Mead Johnson, maker of Enfamil, controlled another 40%. By comparison, Nestlé was a distant third with just 15%. 
  • The move comes after the FDA said it was encouraging overseas manufacturers to apply to ship their formula to the U.S., easing rules that had effectively prevented shipments from many such companies.
  • Abbott on Monday said it had reached an agreement with the FDA for the reopening of the Sturgis plant.
  • Photo by Company
  • 歐洲的雀巢公司美國場外交易市場代碼：NSRGF)正在增加低過敏性(HA)嬰兒配方奶粉的生產，以緩解美國超市的短缺。
  • 在發送到的聲明中財運雀巢表示，它“顯著增加了”來自荷蘭的Gerber Good Start廣泛生產的HA和來自瑞士的Alafino，這兩種產品都用於治療對乳糖等糖過敏的嬰兒。
  • 雀巢拒絕透露增加出貨量的更多細節。
  • 召回雅培(紐約證券交易所股票代碼：ABT)、持續的供應鏈問題和高度集中的市場結合在一起，形成了一位消費品專家所説的“完美風暴”。
  • 相關： 美國國會議員公佈FDA緊急資金法案以解決嬰兒配方奶粉短缺問題：路透社.
  • 最新的統計數據顯示，雅培擁有43%的市場份額，而安非他明的製造商美贊臣則控制着另外40%的市場份額。相比之下，雀巢僅佔15%，遠遠落後於第三名。
  • 在此之前，FDA表示正在鼓勵海外製造商申請將其配方奶粉運往美國，放鬆了實際上阻止許多此類公司發貨的規定。
  • 雅培週一表示，已與FDA就斯特吉斯工廠的重新開放達成協議。
  • 照片由公司提供
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論